CD28‐Targeted Enzyme‐Responsive Conformation‐Switching Peptide Self‐Assembly for Selective T‐Cell Acute Lymphoblastic Leukemia (T‐ALL) Therapy
-CD28 demonstrated potent antitumor activity, and its combination with cytarabine resulted in near-complete tumor suppression, highlighting its potential for T-ALL treatment. This work introduces a CD28-targeted, enzyme-activated nanotherapeutic strategy that synergizes biochemical and mechanical mechanisms to selectively eliminate T-ALL cells. This multi-mechanistic tumor-killing strategy can also be extended to inspire therapeutic approaches for other diseases.
Authors
- Man‐Di Wang (ORCID: https://orcid.org/0009-0002-2464-839X)
- Su Tuo
- Shengyi Zhang (ORCID: https://orcid.org/0000-0002-4542-4523)
- Huisheng Fu
- Yinghao Ding (ORCID: https://orcid.org/0009-0000-7710-0155)
- Zhimou Yang
- Ziyu Jia
- Dekun Li
- Jun Li
- Ling Wang
Institutions
- Nankai University (CN)
- Tianjin Medical University General Hospital (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2026-04-02
- DOI
- https://doi.org/10.1002/advs.202520963
- Primary Topic
- Supramolecular Self-Assembly in Materials
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China